Agios Pharmaceuticals (NASDAQ:AGIO) Share Price Passes Below Two Hundred Day Moving Average – Should You Sell?

Shares of Agios Pharmaceuticals, Inc. (NASDAQ:AGIO) crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $33.61 and traded as low as $29.80. Agios Pharmaceuticals shares last traded at $29.96, with a volume of 647,584 shares traded.

Analyst Ratings Changes

Several equities research analysts have issued reports on AGIO shares. Wall Street Zen upgraded shares of Agios Pharmaceuticals from a “sell” rating to a “hold” rating in a research note on Saturday, February 14th. Royal Bank Of Canada downgraded Agios Pharmaceuticals from an “outperform” rating to a “sector perform” rating and lowered their price target for the company from $57.00 to $28.00 in a report on Wednesday, November 19th. The Goldman Sachs Group dropped their price objective on shares of Agios Pharmaceuticals from $40.00 to $25.00 and set a “neutral” rating on the stock in a research note on Thursday, November 20th. Citigroup reiterated a “buy” rating on shares of Agios Pharmaceuticals in a research note on Friday, December 26th. Finally, JPMorgan Chase & Co. lifted their price target on Agios Pharmaceuticals from $20.00 to $25.00 and gave the company a “neutral” rating in a report on Tuesday, January 6th. Six research analysts have rated the stock with a Buy rating, four have issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $39.78.

Agios Pharmaceuticals Stock Performance

The company’s 50 day moving average price is $27.72 and its 200 day moving average price is $33.61. The company has a market cap of $1.76 billion, a price-to-earnings ratio of -4.21 and a beta of 0.91.

Insiders Place Their Bets

In other news, CFO Cecilia Jones sold 2,932 shares of Agios Pharmaceuticals stock in a transaction that occurred on Tuesday, December 30th. The shares were sold at an average price of $27.09, for a total transaction of $79,427.88. Following the completion of the sale, the chief financial officer owned 37,394 shares in the company, valued at $1,013,003.46. The trade was a 7.27% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO Brian Goff sold 18,703 shares of the company’s stock in a transaction dated Tuesday, December 30th. The shares were sold at an average price of $27.09, for a total value of $506,664.27. Following the completion of the sale, the chief executive officer directly owned 136,583 shares of the company’s stock, valued at approximately $3,700,033.47. This trade represents a 12.04% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. Insiders sold a total of 33,303 shares of company stock worth $901,977 in the last 90 days. 4.30% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Agios Pharmaceuticals

Several institutional investors and hedge funds have recently added to or reduced their stakes in the business. T. Rowe Price Investment Management Inc. bought a new stake in Agios Pharmaceuticals in the 4th quarter valued at $25,000. Invesco Ltd. increased its holdings in shares of Agios Pharmaceuticals by 12.3% during the fourth quarter. Invesco Ltd. now owns 142,580 shares of the biopharmaceutical company’s stock worth $3,881,000 after purchasing an additional 15,604 shares during the period. XTX Topco Ltd acquired a new stake in shares of Agios Pharmaceuticals in the fourth quarter valued at approximately $1,253,000. VARCOV Co. bought a new stake in shares of Agios Pharmaceuticals in the fourth quarter valued at approximately $520,000. Finally, Vestal Point Capital LP grew its position in Agios Pharmaceuticals by 155.9% during the fourth quarter. Vestal Point Capital LP now owns 325,000 shares of the biopharmaceutical company’s stock worth $8,846,000 after buying an additional 198,000 shares in the last quarter.

Agios Pharmaceuticals Company Profile

Agios Pharmaceuticals, Inc is a biopharmaceutical company founded in 2008 as a spin-out from research at Dana-Farber Cancer Institute and the Broad Institute. Headquartered in Cambridge, Massachusetts, Agios focuses on understanding and targeting cellular metabolism to develop novel therapies for cancer and rare genetic diseases. The company’s scientific platform integrates genomic discovery, metabolic profiling and precision medicine approaches to identify and advance small-molecule candidates that correct or exploit metabolic dysfunction.

Agios’s lead products are IDH (isocitrate dehydrogenase) inhibitors that target specific cancer mutations.